This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (9)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Current Food and Drug Administration Regulations and Statistical Aspects of Clinical Trials

Bruce A. Barron, PhD; Samuel C. Bukantz, MD

Arch Intern Med. 1967;119(6):547-556.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In THIS paper the current Food and Drug Administration (FDA) regulations pertaining to the testing of new drugs are reviewed, and a basic statistical issue of the design of a clinical trial is discussed. The regulatory procedures that are described are applicable to any sponsor of a clinical trial—whether that sponsor is a pharmaceutical corporation, a department of pharmacology within a medical school, or an individual. The validity of any conclusion concerning the effects of a new drug—both beneficial and adverse—is dependent upon the experimental design of the trial. The statistical principle discussed here provides a ruler with which to measure the sensitivity of the design of a clinical trial.

Kefauver-Harris Amendments

Prior to the passage of the 1938 Food, Drug, and Cosmetic Act, drugs could be marketed before "clearance" by the Federal Government. The clearance procedures established by the 1938 act were limited to tests for safety. The 1962 . . . [Full Text PDF of this Article]

Author Affiliations
New York

From Rockefeller University (Dr. Barron) and University Hospital, New York University (Dr. Bukantz), New York.

Footnotes
Received for publication Jan 9, 1967; accepted Feb 6.

Reprint requests to Rockefeller University, New York 10021 (Dr. Barron).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?